Cosmo Pharmaceuticals (SWX:COPN) Is Up 46.9% After Expanding Its Clascoterone Dermatology Franchise
Cosmo Pharmaceuticals recently reported successful Phase III results for its Clascoterone 5% solution in male hair loss and…
Browsing Tag
regulatory risk
1 post